Abstract
The European Commission on Public Health defines rare diseases as “life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them” (<1:2000 people). Diseases that are statistically rare, but not also life-threatening, chronically debilitating, or inadequately treated, are excluded from their definition. Rare diseases are seen among migrants, but are generally not diagnosed. A group, however, that should be recognized and diagnosed are the neglected tropical diseases (NTDs), in particular because they are usually treatable and in the countries of origin of the migrants they are not rare.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
NCATS. https://ncats.nih.gov/sites/default/files/factsheet-trnd.pdf.
EspeRare Foundation. http://esperare.org/en/addressing-rare-diseases.
Naafs B, van Hees CLM, van Ingen J. Mycobacterial (skin) infections. Chapter VI. In: Ólafsson JH, Hay RJ, editors. Antibiotic and antifungal therapies in dermatology. Cham, Switzerland: Springer; 2017. p. 81–139.
Dos Santos JB, Figueiredo AR, Ferraz CE, et al. Cutaneous tuberculosis: epidemiologic, etiopathogenic and clinical aspects - Part I. An Bras Dermatol. 2014;89(2):219–29. https://doi.org/10.1590/abd1806-4841.20142334.
Ramesh V, Misra RS, Jain RK. Secondary tuberculosis of the skin: clinical features and problems in laboratory diagnosis. Int J Dermatol. 1987;26:578.
Marcoval J, Alcaide F. Evolution of cutaneous tuberculosis over the past 30 years in a tertiary hospital on the European Mediterranean coast. Clin Exp Dermatol. 2013;38:131–6.
Faber WR. Mycobacterial infections, chap: 7. In: Faber WR, Hay JR, Naafs B, editors. Imported skin diseases. 2nd ed. Chichester, England: Wiley; 2013. p. 64–78.
Rapini R, Bolognia JL, Jorizzo JL. Dermatology, vol. 2, chap. 74. St. Louis: Mosby; 2007. p. 27.
Yates VM. Mycobacterial infections. In: Burns T, Breatnach S, Cox N, Griffiths C, editors. Rook’s textbook of dermatology. 8th ed. Oxford: Blackwell Science; 2010. p. 31.21–2.
Sharon V, Goodarzi H, Chambers CJ, et al. Erythema induratum of Bazin. Dermatol Online J. 2010;16:1.
Dooley KE, Obuku EA, Durakovic N, et al. Efficacy subgroup, RESIST-TB, World Health Organization group V. Drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013;207:1352–8.
WHO. http://www.who.int/tb/areas-of-work/drug-resistant-tb/xdr-tb-faq/en.
WHO. http://www.who.int/tb/areas-of-work/monitoring-evaluation/mdr-tb-surveillance/en/.
WHO. Weekly epidemiological record. No. 35. 2013;88:365–380.
Bjune G, Barnetson RS, Ridley DS, Kronvall G. Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin Exp Immunol. 1976;25(1):85–94.
Naafs B. Reactions: new knowledge. Trop Geogr Med. 1994;46:80–4.
Velarde-Félix JS, Alvarado-Villa G, Vera-Cabrera L. “Lucio’s phenomenon” associated with Mycobacterium lepromatosis. Am J Trop Med Hyg. 2016;94(3):483–4. https://doi.org/10.4269/ajtmh.15-0439.
Naafs B. Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr Rev. 2003;74:328–36.
AIFO. http://english.aifo.it/leprosy/documents/treatment_of_reactions_b_naafs.pdf.
Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle. 1981;62(1):55–62.
Noordeen SK. Prophylaxis—scope and limitations. Lepr Rev. 2000;71(Suppl):S16–9. discussion S19–20.
Richardus RA, Alam K, Pahan D, et al. The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study). BMC Infect Dis. 2013;13:456.
Walsh DS, Meijers WM, Portaels F. Buruli H9. In: Faber WR, Hay JR, Naafs B, editors. Imported skin diseases. 2nd ed. Chichester, England: Wiley; 2013. p. 94–106.
Stinear TP, Mve-Obiang A, Small PL, et al. Giant plasmid encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A. 2004;101:1345–9.
Walsh DS, Portaels F, Meyers WM. Buruli ulcer: advances in understanding Mycobacterium ulcerans infection. Dermatol Clin. 2011;29:1–8.
Merritt RW, Walker ED, Small PL, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis. 2010;4:e911.
Stop Buruli Consortium. UBS Optimus Foundation: http://www.stopburuli.org/.
Herbinger KH, Adjei O, Awua-Boateng NY, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis. 2009;48:1055–64.
Meyers WM. Mycobacterial infections of the skin. In: Doerr W, Seifert G, editors. Tropical pathology. 2nd ed. Berlin: Springer; 1995. p. 291–377.
Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182–6.
http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf?ua=1.
Van Ingen J. Nontuberculous mycobacteria from gene sequences to clinical relevance. Thesis Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, 21 Sept 2009.
Han X, Tarrand JJ, Infante R, et al. Clinical significance and epidemiologic analyses of mycobacterium avium and mycobacterium intracellulare among patients without AIDS. J Clin Microbiol. 2005;4:4407–12.
Falsey RR, Kinzer MH, Hurst S, et al. Cutaneous inoculation of nontuberculous mycobacteria during professional tattooing: a case series and epidemiologic study. Clin Infect Dis. 2013;57:e143–7.
van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15:149–61.
Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother. 2007;8:2965–78.
Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med. 2008;29:569–76.
Griffith DE, Aksamit T, Brown-Elliott BA, et al., on behalf of the ATS Mycobacterial Diseases Subcommittee American Thoracic Society Documents. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases adopted by the ATS Board of Directors, 2006, and by the IDSA Board of Directors, 2007. Am J Respir Crit Care Med 2007;175:367–416.
Nagore E, Ramos P, Bottella-Estrada R, et al. Cutaneous infection with Mycobacterium fortuitum after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. Acta Derm Venereol. 2001;81:291–3.
Van Ingen J, Boeree M, Janssen M, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol. 2007;3:414–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Naafs, B., Hay, R., Morrone, A. (2020). Rare Diseases Including NTDs and Their Management. In: Morrone, A., Hay, R., Naafs, B. (eds) Skin Disorders in Migrants. Springer, Cham. https://doi.org/10.1007/978-3-030-37476-1_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-37476-1_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-37475-4
Online ISBN: 978-3-030-37476-1
eBook Packages: MedicineMedicine (R0)